Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phencynonate vs betahistine for acute vertigo
ChiCTR2600119785Phase 4Not yet recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of phencynonate hydrochloride in acute vestibular syndrome (AVS), Meniere Disease, vestibular neuritis and 1 more (2 arms), sponsored by Xuanwu Hospital. Primary endpoint: Duration of dizziness after medication compared with betahistine group. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
phencynonate hydrochloride
03
Conditions
acute vestibular syndrome (AVS)Meniere Diseasevestibular neuritisacute sensorineural hearing loss
Beyond the preview
Go deeper on ChiCTR2600119785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119785.